17-20 Based on this evidence, the coding region and a putative promoter region were sequenced in ten autistic subjects. Several polymorphisms were detected, but no evidence was found for a functional mutation. Evidence for likely altered regulation of UBE3A expression in maternal 15q11-q13 duplications suggests further investigation of the regulatory regions of this gene in autistic disorder.
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Duplications of 15q11-q13 of maternal origin are the most consistent chromosomal abnormalities detected in autistic disorder. [1] [2] [3] [4] [5] [6] [7] [8] 11 Recently, it was shown in five families that these duplications cause autism or other developmental disorders when maternally but not paternally derived. [9] [10] [11] Studies of autistic populations suggest that at least 1% of the cases may be accounted for by chromosome 15 abnormalities. 5, 11, 21 In contrast, maternal deletions of this same region cause Angelman Syndrome (AS), a disorder typified by mental retardation, seizures, ataxia, and inappropriate laughter. Truncating mutations in UBE3A, which encodes the E6-AP ubiquitin-protein ligase gene, have also been found to cause familial AS. 12, 13 The presence of autism in many patients with AS 22 allows for the possibility that a maternally transmitted mutation of smaller effect could lead to a milder phenotype that could resemble autistic disorder. 23 Mutations in UBE3A or its regulatory elements are also excellent candidates for mimicking the effects of maternal duplication of this region. Currently, UBE3A is the only gene in the 15q11-q13 region found to exhibit maternally imprinted expression in regions of interest in autism. Autopsy studies in adult humans have revealed that certain mRNA transcripts of UBE3A are solely maternally expressed in the brain but are expressed biparentally elsewhere in the body.
14 mRNA expression studies suggest that all transcripts of UBE3A are predominantly maternally derived in total fetal human brain. 15 Furthermore, evidence from the mouse indicates the hippocampus and the cerebellar Purkinje cells as the primary areas where expression is solely from the maternal chromosome. 16 Abnormalities in cerebellar size and structure have been the most frequent brain correlate to autism, both in post mortem 17 and MRI studies. 18, 19 Cytoarchitectural abnormalities in the hippocampus have also been identified in a post mortem study of autistic subjects. 20 Based on these separate lines of evidence, truncating mutations of UBE3A in AS, imprinting of UBE3A in brain regions implicated in autism, and maternal 15q11-q13 duplications in autistic disorder, UBE3A is a strong candidate gene in autistic disorder. We used sequence ascertained in determining the genomic organization of the gene to design primer sets to screen the coding region, one portion of a 5Ј UTR exon, and a putative promoter sequence for mutations in autistic subjects.
Ten autistic subjects were sequenced in both directions for each of the 12 primer sets shown in Table 1 . Screening of the coding region in ten autistic subjects revealed no mutations that would be likely to be responsible for disrupting expression or activity of the UBE3A gene product. Additionally, no mutations were found in the area between exons 4 and 5 which has been predicted to be a promoter region 15 (exon naming conventions from Kishino and Wagstaff). 23 Finally, no mutations were detected in exon 6, which when transcribed contains a stop codon that terminates translation that begins at start codons in exons 4 or 5, rather than the usual start codon in exon 7.
Three polymorphisms were detected in the mutation screen, none of which affects amino acid sequence. Table 2 shows the positions of these three polymorphisms and four other known polymorphisms in close proximity to the UBE3A gene relative to a PAC genomic clone (GenBank Accession No. AC004259) that includes almost the entire gene. One of the three polymorphisms observed, a 3-bp deletion in intron 7 of bases 408-410 of the exon 8 genomic sequence (GenBank Accession No. AF016704), had been previously identified in a population of AS subjects (Beaudet, unpublished data) and tested for linkage disequilibrium in autistic disorder subjects. 21 A 9-10 T repeat polymorphism was identified in intron 6 from bases 373-381 of the exon 7 genomic sequence (GenBank Accession No. AF016703). A G to C transversion that fails to alter the amino acid sequence was identified within the coding sequence at base 687 of Figure 1 Map of UBE3A on chromosome 15. The two new polymorphisms detected in this mutation screen are indicated and underlined. Five previously identified polymorphisms are also indicated. D15S122, D15S10, the OP2 7-bp deletion, and the intron 7 3-bp deletion, were previously tested for linkage disequilibrium with autistic disorder. 21 The repeat within exon 16 in the 3Ј UTR 30 has not yet been tested for linkage disequilibrium with autistic disorder. Exons are shown by solid boxes. The GABRB3 155CA-2 marker found to be in linkage disequilibrium with autistic disorder 21 is telomeric to UBE3A, as is D15S156, the marker where a suggestive linkage finding peaked. Linkage disequilibrium mapping of the 15q11-q13 region revealed significant family-based association between autistic disorder and the GABRB3 155CA-2 marker, also distal to UBE3A. 21 A preliminary finding of linkage in autistic disorder began at GABRB3 markers, extended telomerically, and peaked at the D15S156 marker, distal to the UBE3A gene on chromosome 15. 24 No significant linkage disequilibrium was detected between four markers within the UBE3A gene and autism. 21 However, given the evidence for maternal imprinting of UBE3A expression in the brain, linkage disequilibrium findings may be weakened since only maternal transmissions may be informative.
The well-documented finding of 15q11-q13 maternal duplication events in autism suggests that an alteration in the UBE3A gene product's activity could be found in subjects with autistic disorder. In patients without this duplication, an alteration in activity could derive from either altered gene expression due to a change in regulatory elements or dysregulation of the protein's activity due to a change in the coding sequence. The absence of a coding region mutation in this current study suggests the former as a more likely possibility.
The continuing localization of mutations in Angelman Syndrome 25 may assist in this effort by identifying areas outside of the known coding region that merit screening in autism. Some caution must be taken in interpreting these results due to the small sample size. Additionally, one reported crossover in a familial AS case has been localized telomeric to D15S122, 26 which would implicate a disruption in the untranslated first exon or in 5Ј regulatory elements, neither of which was covered in the present mutation screen. Analysis of the promoter region or other regulatory gene elements 
Mutation screen
Oligonucleotide primers were designed from genomic sequence flanking the exons of the UBE3A coding region. The primers, with their annealing temperatures and positions, are listed in Table 1 . Amplification was carried out in a total volume of 10 l containing 0.5 M of each primer, 200 M of each dNTP (Perkin Elmer, Foster City, CA, USA), 2.5 mM MgCl 2 , 10 mM Tris-HCI, 50 mM KCI, 0.001% gelatin, 0.3 Units of AmpliTaq Gold DNA Polymerase (Perkin Elmer), and 50 ng of DNA template. DNA was extracted from the blood of 10 subjects seen at the University of Chicago Developmental Disorders Clinic as previously described. 21 PCR was performed on a Perkin Elmer 9600 thermocycler with an initial activating step of 95°C for 12 min, followed by 40 cycles of PCR: denaturing at 94°C for 15 s, annealing at optimum temperature (see Table 1 ) for 30 s, and extension at 72°C for 30 s, and followed by a final extension step of 72°C for 2 min. PCR products were sized on 4% agarose gels, and excised fragments were extracted using the QIAquick Gel Extraction Kit (Qiagen, Valencia, CA, USA). Cycle sequencing was performed using the ABI prism dRhodamine Terminator Cycle Sequencing Ready Reaction Mix (PE Applied Biosystems, Foster City, CA, USA) on the Perkin Elmer 9600 thermocycler. Sequencing fragments were separated by capillary electrophoresis and detected by laser-induced fluorescence on an ABI prism 310 Genetic Analyzer using POP6 polymer (PE Applied Biosystems).
